Boehringer Ingelheim and 3T Biosciences entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation cancer immunotherapies.
 
This second research partnership with 3T builds on the successful completion of the initial research partnership leveraging 3T’s best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform and Boehringer’s immuno-oncology efforts to boost the immune system’s ability to recognize, attack and kill tumors.
 
Boehringer will provide patient-derived T-cell receptor (TCR) data for 3T’s target discovery efforts to identify cognate antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and R&D support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones for both agreements totaling $538.5 million, in addition to royalties on future Boehringer product sales. Boehringer is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
 
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. The initial success of our work with 3T gives us confidence that together we can and will expand and accelerate our pipeline of first-in-class T-cell based anti-cancer therapies,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology and Immune Modulation, Boehringer Ingelheim.
 
“The work we have done with Boehringer Ingelheim over the past year provides a higher degree of validation of our 3T-TRACE discovery platform,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “Based on the success of this initial work, we will now go broader and deeper into other cancers.”